Melitus

Melitus Pharma is a clinical-stage biopharmaceutical company dedicated to the development of novel treatments for metabolic disorders, with a primary focus on diabetes. The company's lead asset, MBX-2982, is a potent, selective G protein-coupled receptor 119 (GPR119) agonist designed to enhance insulin secretion and improve glucose control. Melitus is actively exploring the potential of its candidates in both Type 1 and Type 2 diabetes through strategic collaborations with organizations like JDRF and the University of Florida. Headquartered in Germany, the company utilizes its deep expertise in GPCR signaling to address unmet needs in endocrinology. The company's approach focuses on oral small molecules that can provide disease-modifying benefits for patients with chronic metabolic conditions.